Demand for genomic benefits is growing. Value should too.
MyOme sequences the whole genome, surfaces risk across diseases and medication response, and includes board-certified genetic counseling with every result.
The opportunity
Demand for genomic benefits is growing. Value should too.
Genomic health benefits are quickly becoming a fixture in competitive benefits packages. But most tests being offered — including those deployed at Fortune 500 companies — sequence less than 2% of the genome, cover only one disease area, or come without clinical support1–3. MyOme sequences the whole genome, surfaces risk across diseases and medication response, and includes board-certified genetic counseling with every result.
1. Cohn B, et al. Molecular Genetics & Genomic Medicine (2023). 2. Society for Human Resource Management, 2018 Employee Benefits. 3. McDonald WS, et al. Molecular Genetics & Genomic Medicine (2020).
MyOme benefits package
Whole-genome coverage, not a 2% panel
Medication response
70+ medicationsComplex disease risk
Genetic counseling
Board-certified consultations included with every result.
Learn moreHidden risk
How many of your employees are carrying preventable health risks?
MyOme Atlas tests identify disease risks before symptoms appear, catching what routine checkups miss, and predict how employees will respond to medications, speeding the journey to the right treatment. Together, these insights personalize preventive care, reduce adverse drug reactions, and lower healthcare costs before they compound.
| Coronary artery disease | Approximately 50 percent of risk is attributable to genetic factors. |
|---|---|
| Breast cancer | Approximately 50 percent of risk is attributable to genetic factors. |
| Prostate cancer | Approximately 70 percent of risk is attributable to genetic factors. |
| Type 2 diabetes | Approximately 70 percent of risk is attributable to genetic factors. |
| Medication response findings | Approximately 95 percent of employees have genetic factors that may impact medication responses. |
Proven uptake and impact
A benefit employees actually use
Employee participation
of employees engaged in the program within 90 days of access to MyOme testing
Disease risk detection
of employees tested carried at least one clinically significant, high-impact risk variant linked to a health condition
High-risk classification
of employees were identified as high-risk for cardiometabolic disease or cancer
Results averaged across active employer programs.
What our partners say
More than 50% of cancers and up to 80% of cardiac diseases are preventable. By integrating genomics into employer health programs, we provide participants with knowledge that can save lives and significantly improve outcomes.
Reduce healthcare spend
How genomic risk insights shape care
Many of the most expensive healthcare claims stem from conditions that can be identified and addressed earlier.
Reduction in hospitalizations
Medication Response insights enable safe prescribing from the start. This type of screening is proven to reduce medication-related ER visits and inpatient stays by ~40%.1
Savings in treatment costs
Curated Screen insights for cancers, including breast cancer, can stimulate early screening, detection, and treatment. Treating breast cancer early can reduce treatment costs by >$500K.2
Savings in post-event care
Polygenic risk scores for coronary artery disease can lead to early interventions — like statin therapy — that reduce heart event risk and avoid $40K in annual treatment costs.3
- Fragala MS, Keogh M, Goldberg SE, Lorenz RA, and Shaman JA. The Pharmacogenomics Journal. 2 Oct 2024; 24(5):30. doi: 10.1038/s41397-024-00350-1.
- Reddy SR, Chung KC, Kansal AR, et al. Current Medical Research and Opinion. 2022; 38(5):791-800. doi: 10.1080/03007995.2022.2047536.
- Kazi DS, Elkind MSV, Deutsch A, et al. Circulation. 23 Jul 2024; 150(4):e89-e101. doi: 10.1161/CIR.0000000000001258.
Employee support and privacy
Results are the employee's — always
Every employee receives their results privately, with access to a certified genetic counselor to help them understand findings and plan next steps. Your organization sees only aggregate, de-identified program data — never individual results. All genomic data is encrypted, HIPAA-compliant, and never shared without the employee's explicit consent.
Privacy and security
Get in touch to find the right program
We want to help you find the right program for your organization and employees. Reach out to learn more about how MyOme can elevate your health benefit offerings with precision risk insights.